The pharmaceutical sector’s focus will shift from companies to patients while players in sectors like information technology, retail and telecommunication will also become stakeholders in the pharmaceutical sector, says Ernst & Young’s annual global pharmaceutical report ‘Progressions, Pharma 3.0’, which was released in Mumbai on Wednesday.
“Companies realise that the road ahead will become more complex with the entry of new players, which are being lured to the sector in increasing numbers. The global pharmaceutical companies are increasingly exploring alliances with nontraditional partners as a way to pursue opportunities in emerging markets. Emerging markets, such as India, will play a crucial role in promoting these opportunities and adoption of Pharma 3.0” said Hitesh Sharma, partner and national leader, Life Sciences Practice, Ernst & Young.